Sakar Healthcare Ltd

The company exhibits a mixed financial performance. On one hand, it has achieved strong sales growth. The compounded sales growth over 3 years stands at 24%, and annual sales for March 2024 grew by nearly 15%. Operating profit margins have also remained stable and healthy, hovering around 25% annually, indicating good operational control at the gross level. However, this top-line strength does not translate to the bottom line. Annual net profit has declined for two consecutive years, falling by 16% in March 2023 and another 10% in March 2024. This divergence is also reflected in the declining net profit margin, which fell from 11.7% in FY22 to 7.8% in FY24. Quarterly profit growth is highly volatile, indicating a lack of earnings consistency and predictability. The financial performance is marked by a clear disconnect between robust revenue expansion and deteriorating profitability.

The company's capital efficiency and returns on investment are weak and show a declining trend. The Return on Capital Employed (ROCE) has seen a steady erosion, falling from 12% in March 2022 to a mere 7% in March 2024. This suggests that the incremental capital invested in the business is generating lower returns, pointing to inefficient capital allocation. Similarly, the Return on Equity (ROE) is low, standing at 6.48% currently and 10% for the last year, which indicates poor returns for shareholders' funds. The Asset Turnover ratio has also worsened, declining from 0.48 in FY22 to 0.39 in FY24, meaning the company is generating less revenue for every rupee of assets it holds. Furthermore, the Cash Conversion Cycle (CCC) has increased from -39 days in March 2022 to 51 days in March 2024, indicating that more cash is being tied up in working capital.

The company's financial health shows signs of prudence, particularly in its recent debt management. After a period of leveraging up to fund expansion, where borrowings peaked at 119 Cr in March 2023, the management has successfully reduced debt to 79 Cr in March 2024. This has brought the debt-to-equity ratio down from a moderate 0.69 to a more comfortable 0.30. This deleveraging demonstrates financial discipline. The Interest Coverage Ratio (ICR), calculated as Operating Profit divided by Interest, stood at a healthy 4.75x in March 2024. While this is a dip from the previous year's 5.5x due to higher interest costs, it is still well above a safe threshold, indicating the company can comfortably service its interest obligations. The consistent zero percent dividend payout is a minor weakness, although common for companies reinvesting all earnings for growth.

The shareholding structure presents a significant area of concern despite some positive developments. The most alarming trend is the consistent and substantial decrease in promoter holding. The promoters have reduced their stake from 74.02% in March 2021 to 53.15% by March 2024, a dilution of over 20 percentage points in just three years. Such a significant offloading by insiders raises serious questions about their long-term confidence in the business. On a more positive note, this gap has been filled by institutional investors. Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) together hold over 24%. The presence of institutional investors typically lends credibility. However, the confidence shown by institutions is juxtaposed against the apparent lack of confidence from the promoters. The sharp decline in promoter ownership is a dominant negative factor that weakens the overall assessment of the ownership structure.

Several accounting-related red flags are present. The most prominent is the significant and continuous reduction in promoter shareholding, which has fallen from 74% to 53% in three years. This raises concerns about the promoters' confidence in the company's future. Another flag is the divergence between strong sales growth and declining annual net profit. This suggests either significant margin pressure or issues with converting revenue into actual profit. While the cash flow from operations is positive, the volatile working capital changes and a rising cash conversion cycle indicate potential inefficiencies in managing day-to-day operations.

The company has a notable exposure to interest rate risk. To fund its capital expenditure, borrowings increased significantly, causing interest expenses to rise from 2 Cr in FY21 to 8 Cr in FY24. This four-fold increase in interest payments puts pressure on the company's profitability. Although the Interest Coverage Ratio of 4.75x in FY24 indicates that the company can currently service its debt, its profitability remains sensitive to fluctuations in interest rates. A higher interest rate environment would further erode the already declining net profits. The debt reduction in FY24 is a positive step in mitigating this risk, but the existing interest burden remains a moderate concern.